Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
AGC Biologics
Sort By
Newest First
1 / 2
1 / 2
AGC Biologics Completes pDNA and mRNA Expansion at Heidelberg location
AGC Biologics
PR-M10-23-02
October 12, 2023
Cell Therapy Manufacturing
RoosterBio and AGC Biologics Announce Collaboration to Accelerate Manufacturing of Cell and Exosome Therapies
AGC Biologics
PR-M08-22-03
August 16, 2022
Unmet Needs
In which orphan spaces or unmet medical needs do you think we will see the next treatment innovations?
Pharma's Almanac
PAO-06-022--RT-01
June 24, 2022
Industry Challenges
What do you consider the biggest challenge that the pharma/biopharma industry currently faces?
Pharma's Almanac
O-06-022--RT-01
June 24, 2022
New Facility
AGC Biologics Invests in Viral Vector Suspension at New U.S. Campus
AGC Biologics
PR-M05-22-13-359
May 18, 2022
Leadership
Q: What’s the key to being a leader in the industry?
Pharma's Almanac
PAO-03-022-RT-02
March 11, 2022
Milestones
Q: What important company milestone do you anticipate reaching in 2022?
Pharma's Almanac
PAO-03-022-RT-01
March 11, 2022
COVID-19 Vaccine
AGC Biologics Supports Omicron-Based Vaccine Candidate Manufacturing with Starting Material
AGC Biologics
PR-M02-22-07
February 09, 2022
Personalized and Precision Medicine
Q: What do you see as the key innovations or technologies that will make personalized/precision medicine a reality?
Pharma's Almanac
PAO-12-21-RT-01
January 07, 2022
Therapeutic Progress
Q: For what therapeutic area do you think we will see the greatest progress in the coming years?
Pharma's Almanac
PAO-12-21-RT-02
January 07, 2022
Expansion
AGC Biologics Expands pDNA and mRNA Manufacturing Capacity at Heidelberg Facility
AGC Biologics
PR-M09-21-04
September 14, 2021
Partnership
Novavax Selects AGC Biologics to Manufacture Matrix-M Adjuvant for Novel COVID-19 Vaccine
AGC Biologics
PR-M06-20-NI-008
June 05, 2020
Expansion
AGC Biologics Expands Plasmid DNA Offering
AGC Biologics
PR-M12-19-NI-030
December 20, 2019
Antibody-Drug Conjugate
Fast-Tracking ADC Development and Commercialization
Matteo Piazza
PROVEO
PAP-Q4-19-CL-003
December 06, 2019
Customer Centricity
Uniting Innovation and Customer-Centricity
Patricio E. Massera
AGC Biologics
PTV-M08-19-BIO-001
August 12, 2019
Customer Focus
Designing a Customer-Centric CDMO
Patricio E. Massera
AGC Biologics
PAP-Q2-2019-CL-003
May 24, 2019
Appointment
Dr. Gustavo Mahler Resigns as Chief Executive Officer of AGC Biologics, Patricio Massera to Succeed as CEO Effective May 1st, 2019
AGC Biologics
PR-M04-19-NI-032
April 04, 2019
Biologics Manufacturing
AGC Triples U.S. Biopharmaceutical Production Capacity
AGC Biologics
PR-M12-18-NI-066
December 18, 2018
Contract Manufacturing Needs
Meeting Biopharma Contract Manufacturing Needs with a Flexible Global Network
Gustavo Mahler, Ph.D.
Dynamk Capital
PAP-Q2-18-CL-006
May 29, 2018
Supply Agreement
AGC Biologics Enters into Commercial Supply Agreement with MacroGenics
AGC Biologics
PR-M05-18-NI-053
May 15, 2018
